Prevention of Chronic Allograft Rejection Using Angiogenesis Inhibitors
Inventors: David Briscoe, Karen Moulton, Mohamed Sayegh
Invention Types: Therapeutics
Research Areas: Cardiovascular/Cardiology, Immunology, Internal Medicine
Keywords: Anti-angiogenesis, New Indication/Use, Organ Transplant, TransplantationFor More Information Contact: Caron, Connie
Investigators at Children's Hospital Boston have shown in vivo that treatment of an organ donor and/or transplant recipient with angiogenesis inhibitors such as TNP-470 or AGM 1470 decreased chronic organ rejection in the recipient. The vascular endothelium participates in the initiation of graft arteriosclerosis lesions, the characteristic lesion of chronic allograft rejection. Despite advances in techniques for immunosuppression and tissue typing, early ischemia reperfusion injury and acute and chronic transplant rejection remain a serious clinical problem only partially controlled by current immunosuppressive drugs. Current treatments are also associated with the detrimental side effects resulting from impaired immune system function.
Chronic allograft rejection in organ transplantation
Angiogenesis inhibitors can be administered alone or together with traditional immunosuppression agents, and combination treatment could potentially decrease the risk of the detrimental side-effects associated with the addition of immunosuppressive agents.
Exclusive or Non-Exclusive License
Key Publications: Transplantation. 2004 Oct 27;78(8):1218-21.|
J Am Soc Nephrol. 2006 Apr;17 |
J Clin Invest. 2003 Dec;112(11):1655-65.(4):932-42.
Related Publications: US patent number: 6,218,361